Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production

Venetoclax, a Bcl-2 inhibitor, in combination with the hypomethylating agent azacytidine, achieves complete remission with or without count recovery in ∼70% of treatment-naive elderly patients unfit for conventional intensive chemotherapy. However, the mechanism of action of this drug combination is...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood
Главные авторы: Lee, Jong Bok, Khan, Dilshad H., Hurren, Rose, Xu, Mingjing, Na, Yoosu, Kang, Hyeonjeong, Mirali, Sara, Wang, Xiaoming, Gronda, Marcela, Jitkova, Yulia, MacLean, Neil, Arruda, Andrea, Alaniz, Zoe, Konopleva, Marina Y., Andreeff, Michael, Minden, Mark D., Zhang, Li, Schimmer, Aaron D.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2021
Предметы:
Immunobiology and Immunotherapy
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8310428/
https://ncbi.nlm.nih.gov/pubmed/34292323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020009081
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы